Company intelligence / Profile preview

Sumagen

Seoul, Seoul, South Koreasumagen.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Sumagen’s lead program, SAV001—a genetically modified, whole-killed HIV vaccine—has demonstrated both safety and tolerance in human Phase I trials. The company has recently achieved a key milestone in optimizing industrial production with Naobios as its CDMO partner and plans to launch Phase II clinical trials by late 2025.

Therapeutic areas: Infectious Diseases
Modalities: Inactivated whole-virus vaccinesRecombinant genetically modified virus technologyrVSV viral vector platformAntibiotics (via Inferrex acquisition)
Industry: Biotech

Drug pipeline

1 asset

SAV001

Partnerships

Naobios/CDMO partnership for GMP manufacturing of SAV001 and process developmentcollaborations with International Vaccine Institute

Beyond the preview

Go deeper on Sumagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sumagen.

Explore the full profile